Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.